A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Key facts

Study ID

NCT06544655

Run by

Bristol-Myers Squibb

People needed

213

Starts

2024-10-10

Expected to finish

2027-10-14

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
• Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
• Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

You may not qualify if…

• History of or with active interstitial lung disease or pulmonary fibrosis.
• Active, known, or suspected autoimmune disease.
• Serious uncontrolled medical disorders.
• New onset, non-catheter-associated venous thromboembolism within the past 6 months.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 0003 — Tucson, Arizona, United States
• Local Institution - 0007 — Los Angeles, California, United States
• Local Institution - 0011 — Grand Rapids, Michigan, United States
• Local Institution - 0004 — Sioux Falls, South Dakota, United States
• Local Institution - 0013 — San Antonio, Texas, United States
• Local Institution - 0021 — Darlinghurst, New South Wales, Australia
• Local Institution - 0019 — Elizabeth Vale, South Australia, Australia
• Local Institution - 0017 — Toronto, Ontario, Canada
• Local Institution - 0016 — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.